No evidence for capsule replacement...and Wales - Authors' Reply

Lancet Infectious Diseases

Volumn 6, Issue 10, 2006, Pages 617-618

  Snape, MD ^a   Pollard, AJ ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

BACTERIAL MEMBRANE; LETTER; MASS IMMUNIZATION; PHENOTYPE; PRIORITY JOURNAL; SEROTYPE; UNITED KINGDOM;

EID: 33748887778     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70585-0     Document Type: Letter

References (5)

1. Neisseria Multi Locus Sequence Typing website. http://pubmlst.org/neisseria (accessed May 26, 2006)
2. Diggle M., and Clarke S. Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J Clin Microbiol 43 (2005) 4649-4653
3. Lancellotti M., Guiyoule A., Ruckly C., Hong E., Alonso J., and Taha M. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 8 (2006) 191-196
4. Pérez-Trallero E., Vicente D., Montes M., and Cisterna R. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis. Lancet 360 (2002) 953
5. Vazquez J. Experience with meningococcal vaccines. Annual Meeting of the European Society for Paediatric Infectious Diseases; Tampere, Finland; May 26-28, 2004.